C Glaus
Biographic Data
| ID | 8450447 |
|---|---|
| NAME | C Glaus |
| GIVEN NAMES | C |
| FAMILY NAME | Glaus |
| SIGNATURE | GLAUS C |
| AFFILIATIONS | University of Zurich |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
No prominent works on this page.
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
Importance The number of drugs approved through the accelerated approval or conditional marketing authorization pathways has increased with unclear evidence of their therapeutic value. Objectives To assess the therapeutic value of drug indications granted accelerated approval in the US or conditional marketing authorization in the European Union (EU) overall and for cancer indications. Design, Setting, and Participants This cohort study used the …
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Agency (philosophy (2 works) · Business (2 works) · Cohort (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Authorization (1 work) · Bioinformatics (1 work) · Drug (1 work)